Season 15 · Episode 9
S15 Ep9: Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS
OncLive® On Air · OncLive® On Air
December 2, 20254m 16s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In today’s episode, we had the pleasure of speaking with Shubham Pant, MD, MBBS, about the first-line treatment of patients with metastatic pancreatic cancer. Dr Pant is a professor in the Department of Gastrointestinal (GI) Medical Oncology of the Division of Cancer Medicine, director of Clinical Research, and a professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Pant discussed factors that drive frontline chemotherapy selection for metastatic pancreatic cancer, the role of NALIRIFOX (irinotecan liposome [Onivyde], oxaliplatin, 5-fluorouracil, and leucovorin) in this treatment setting, and how the first-line treatment paradigm may evolve and expand going forward.
In our exclusive interview, Dr Pant discussed factors that drive frontline chemotherapy selection for metastatic pancreatic cancer, the role of NALIRIFOX (irinotecan liposome [Onivyde], oxaliplatin, 5-fluorouracil, and leucovorin) in this treatment setting, and how the first-line treatment paradigm may evolve and expand going forward.